Pulmaquin liposomal ciprofloxacin ciprofloxacin regulatory update

FDA granted Fast Track designation to Aradigm's Pulmaquin liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa. The product is in Phase III testing for the indication, for which it also has Qualified Infectious Disease Product (QIDP) designation from FDA. Pulmaquin has Orphan Drug designation in the U.S. and EU for CF and in the U.S. for the management of bronchiectasis. ...